To investigate if differences in imprinting at tropho-microRNA (miRNA) genomic clusters can distinguish between pre-gestational trophoblastic neoplasia cases (pre-GTN) and benign complete hydatidiform mole (CHM) cases at the time of initial uterine evacuation. miRNA sequencing was performed on frozen tissue from 39 CHM cases including 9 GTN cases. DIO3, DLK1, RTL1, and MEG 3 mRNA levels were assessed by qRT-PCR. Protein abundance was assessed by Western blot for DIO3, DLK1, and RTL1. qRT-PCR and Western blot were performed for selenoproteins and markers of oxidative stress. Immunohistochemistry (IHC) was performed for DIO3 on an independent validation set of clinical samples (n = 42) and compared to normal placenta controls across gestational ages. Relative expression of the 14q32 miRNA cluster was lower in pre-GTN cases. There were no differences in protein abundance of DLK1 or RTL1. Notably, there was lower protein expression of DIO3 in pre-GTN cases (5-fold, p < 0.03). There were no differences in mRNA levels of DIO3, DLK1, RTL1 or MEG 3. mRNA levels were higher in all CHM cases compared to normal placenta. IHC showed syncytiotrophoblast-specific DIO3 immunostaining in benign CHM cases and normal placenta, while pre-GTN cases of CHM lacked DIO3 expression. We describe two new biomarkers of pre-GTN CHM cases: decreased 14q32 miRNA expression and loss of DIO3 expression by IHC. Differences in imprinting between benign CHM and pre-GTN cases may provide insight into the fundamental development of CHM.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s43032-021-00634-y | DOI Listing |
Int Immunopharmacol
January 2025
Anhui University of Chinese Medicine, Hefei, Anhui 230012, China.
Objective: In China, Chinese herbal medicines (CHMs) have been widely used in the treatment of psoriatic arthritis (PsA), showing great therapeutic effects in clinical practice. However, due to the great heterogeneity of PsA and the diversity of CHM combination patterns, there is little high-level evidence-based medical research on the treatment of PsA with CHMs. This study aims to explore the beneficial effects of CHMs on the immune inflammation in PsA and its specific mechanism.
View Article and Find Full Text PDFLancet Haematol
January 2025
Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Background: Preliminary data suggest promising activity of loncastuximab tesirine in follicular lymphoma, and synergistic activity between rituximab-induced cytotoxicity and loncastuximab tesirine. In this study, we evaluated loncastuximab tesirine combined with rituximab for second-line and later treatment of follicular lymphoma.
Methods: We did a single-arm, investigator-initiated, phase 2 trial at Sylvester Comprehensive Cancer Center in Miami, FL, USA.
Eur J Obstet Gynecol Reprod Biol X
December 2024
Department of Obstetrics and Gynecology, Maruyama Memorial General Hospital, 2-10-5, Honchou, Iwatsuki-ku, Saitama City, Saitama 339-8521, Japan.
Objective: To reduce the damage of uterine endometrium caused during hysteroscopic myomectomy (HM) for reproductive aged patients, a new uterine endometrium preservation hysteroscopic myomectomy (UEP-HM) has been developed. In this study, we introduced this technique with comparing to the conventional hysteroscopic myomectomy (C-HM).
Study Design: The data from 94 patients aged 42 or younger who underwent HM (38 cases with UEP-HM and 56 cases with C-HM) for treating single Type 1 or Type 2 submucosal leiomyoma (SL) were analysed retrospectively for comparing the characteristics of both patient and target SL.
Int J Reprod Biomed
September 2024
Maternal-Fetal Medicine Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!